Sugi Predict

Sugi Predict / Compounds / SCHEMBL20519

SCHEMBL20519

SCHEMBL20519

O=C(Cl)[C@@H]1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 3/20 0.64
▸ CTRB1 P17538 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.59
▸ KDM1A O60341 1/20 0.59
▸ RCOR1 Q9UKL0 1/20 0.59
▸ TSHR P16473 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ KLK7 P49862 1/20 0.58
▸ KLK5 Q9Y337 1/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ GFER P55789 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL774705 1.00 PREP (0.64) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL205438 1.00 PREP (0.64) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL27881364 0.96 PREP (0.60) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL7246634 0.92 PREP (0.56) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL29553 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL475715 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL205223 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL29658848 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL3680610 0.88 PREP (0.65) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL7326760 0.88 FKBP1A (0.66) PREPCTRB1NPSR1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154051-A1 Method for the preparation of escitalopram H. LUNDBECK A/S (DK) 2005-07-14 — — US claimed
EP-1458701-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. Lundbeck A/S (DK) 2004-09-22 — — EP claimed
WO-2003051861-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. LUNDBECK A/S (DK) 2003-06-26 — — WO claimed
EP-4567035-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2025-06-11 — — EP disclosed
US-20250170092-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF PHARMALA BIOTECH INC. (CA) 2025-05-29 — — US disclosed
CN-118852123-A Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same 株式会社大熊制药 2024-10-29 — — CN disclosed
US-12042478-B2 (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof PHARMALA BIOTECH (CA) 2024-07-23 — — US disclosed
US-12024520-B2 Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide ACERTA PHARMA B.V. (NL) 2024-07-02 — — US disclosed
US-20240051947-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF PHARMALA BIOTECH INC. (CA) 2024-02-15 — — US disclosed
WO-2024030000-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2024-02-08 — — WO disclosed
US-20230303510-A1 CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-09-28 — — US disclosed
WO-1995015310-A1 PROLYL ENDOPEPTIDASE INHIBITORS MERRELL PHARMACEUTICALS INC. (US) 1995-06-08 — — WO disclosed
EP-0635015-A1 ACYLAMINOINDOLE DERIVATIVES AS 5-HT1 AGONISTS. PFIZER (US) 1995-01-25 — — EP disclosed
EP-0619805-A1 INDOLE DERIVATIVES PFIZER HOSPITAL PRODUCTS, INC. (US) 1994-10-19 — — EP disclosed
WO-1994010171-A1 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT1) AGONISTS PFIZER INC. (US) 1994-05-11 — — WO disclosed
EP-0592438-A1 INDOLE DERIVATIVES. PFIZER (US) 1994-04-20 — — EP disclosed
WO-1993021180-A1 ACYLAMINOINDOLE DERIVATIVES AS 5-HT1 AGONISTS PFIZER INC. (US) 1993-10-28 — — WO disclosed
WO-1993011106-A1 INDOLE DERIVATIVES PFIZER, INC. (US) 1993-06-10 — — WO disclosed
WO-1992006973-A1 INDOLE DERIVATIVES PFIZER INC. (US) 1992-04-30 — — WO disclosed
US-4545942-A IMMUNOREGULATORS; ANTITUMOR AGENTS SANKYO COMPANY, LIMITED (JP) 1985-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303510-A1 CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLB, POLH PREP 1602/4885CTRB1 1834/4885NPSR1 4835/4885
US-12042478-B2 (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof NR3C2, PAH, SRD5A1 PREP 1466/4885CTRB1 2060/4885NPSR1 120/4885
US-20240051947-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF NR3C2, PAH, SRD5A1 PREP 1466/4885CTRB1 2060/4885NPSR1 120/4885
US-20050154051-A1 Method for the preparation of escitalopram SLC6A4, TPH2, SLC6A3 PREP 1961/4885CTRB1 3710/4885NPSR1 510/4885
US-12024520-B2 Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide PARP8, CASP8, CYP2C8 PREP 816/4885CTRB1 3354/4885NPSR1 4189/4885
US-20250170092-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF NR3C2, PAH, ADH1C PREP 1304/4885CTRB1 1935/4885NPSR1 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.